Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Business distribution deal

Dr Reddy's Takeda Qdenga India Distribution Deal

Analysis based on 30 articles · First reported Sep 18, 2026 · Last updated Sep 18, 2026

Sentiment
15
Attention
3
Articles
30
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The deal gives Dr. Reddy's an exclusive commercial foothold in India's first approved dengue vaccine, potentially adding a new high-margin private-market revenue stream from 2027 and reinforcing its vaccine franchise. For Takeda, it secures a large-market distribution partner for QDENGA while retaining public-market and brand rights, modestly positive for both companies' growth outlooks though near-term earnings impact is limited given the 2027 launch timeline.

pharmaceuticals vaccines healthcare

Abbott Laboratories and Takeda Pharmaceutical Company announced on September 18, 2026 an exclusive distribution agreement under which Dr. Reddy's will promote and distribute Takeda's dengue vaccine QDENGA across India's private market for pediatric and adult vaccination. The vaccine, India's first approved dengue vaccine, received marketing authorisation from the India — Central Drugs Standard Control Organisation in July 2026 for individuals aged 4-60 years. Subject to completion of applicable processes with local authorities, QDENGA is anticipated to become available in India in the first half of 2027. Under the deal, Dr. Reddy's is the exclusive partner for promotion and distribution in the private market, leveraging its position as India's second-largest vaccine player, its healthcare professional network and nationwide distribution infrastructure. Takeda retains rights to promote and distribute QDENGA in India's public market, as well as legal ownership and overall medical and brand oversight. QDENGA is a live-attenuated tetravalent vaccine providing broad immune coverage across all four dengue serotypes, administered as a two-dose regimen three months apart. It has been approved in more than 40 countries and received prequalification from the World Health Organization, with over 24 million doses distributed globally according to India's Union Health Ministry. Dengue remains a major public health challenge in India, with reported cases increasing 11-fold over the past two decades and all four serotypes co-circulating, according to a study by the India — Indian Council of Medical Research's Virus Research and Diagnostic Laboratory network.

stock
Exclusive private-market distributor of QDENGA in India, gaining a first-mover position in the country's first approved dengue vaccine and a potential new revenue stream from 2027.
Importance 95.0 Sentiment 25.0
stock
Developer and legal owner of QDENGA, securing a strong Indian distribution partner for the private market while retaining public-market and brand oversight rights.
Importance 95.0 Sentiment 20.0
cnt
Gains access to its first approved dengue vaccine through the private market from 2027, addressing a significant public health burden.
Importance 60.0 Sentiment 10.0
govactor
India's drug regulator granted marketing authorisation for QDENGA in July 2026, enabling the subsequent distribution deal.
Importance 45.0 Sentiment 5.0
subs
Takeda's Indian subsidiary party to the distribution agreement, supporting local commercial and regulatory execution for QDENGA.
Importance 40.0 Sentiment 15.0
per
As Takeda's Head of Intercontinental Markets, Mahender Nayak represented Takeda in announcing the collaboration and welcomed the Parliamentary Committee on Health's recommendation on dengue vaccination.
Importance 20.0 Sentiment 0.0
per
As CEO of Global Generics at Dr. Reddy's, R. Ramanan spoke on the significance of introducing India's first approved dengue vaccine and the company's role in addressing the country's dengue burden.
Importance 20.0 Sentiment 0.0
cnt
Home country of Takeda, whose global vaccine export expands through the Indian distribution agreement.
Importance 20.0 Sentiment 5.0
ngo
Prequalified QDENGA and reported record global dengue cases, underscoring the vaccine's public health relevance.
Importance 20.0 Sentiment 5.0
govactor
Its surveillance study documented co-circulation of all four dengue serotypes in India, supporting the case for vaccine rollout.
Importance 15.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.